Navigation Links
Schering-Plough Reports Top-Line Results of the IDEAL Study
Date:1/14/2008

completion of therapy. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths),
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
2. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
3. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Second Thoughts about Fluoride, Reports Scientific American
6. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
9. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
10. Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)
11. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
(Date:8/29/2014)... 29, 2014   Vittamed Corporation , a neurodiagnostics medical ... today that T. (Teo) Forcht Dagi , MD, DmedSc, ... of Directors. " Teo Forcht Dagi ... medical innovation and venture capital," said Remis Bistras , ... add his clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Designs, a company specializing in fashionable medical ID bracelets ... available in an additional 1,100 pharmacies by the end of ... products to more than 1,800. The company ... offering stylish key chains, necklaces, flash drives and bracelets available ...
... 2011 A new prostate cancer study ... surgical treatment to "watchful waiting" revealed important findings ... currently debating their treatment options. (Photo:   ... offered clinical options for early prostate cancer treatment ...
Cached Medicine Technology:Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 2Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 3
(Date:9/1/2014)... The National Association of Hispanic Nurses ( ... DNP, MPH, RN, and Adriana Perez, PhD, Rn, ANP-BC, ... Nursing. They will be inducted with Immediate Past President ... we reported last May. , Our three members will ... American Academy of Nursing Policy Conference in Washington, DC. ...
(Date:9/1/2014)... 2014 Bioinformatics refers to an ... biological and genetic data. A major part of ... software tools to generate and process useful biological ... biological computation. While bioinformatics simply makes use of ... its related concepts, biological computation refers to the ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many web hosting ... Top10BestSEOHosting.com is here to announce that JustHost, Bluehost ... in 2014. , JustHost ( http://www.justhost.com/track/seohosts ) provides ... hosting plan. The company’s approach to hosting is ... accessible and powerful enough for anyone to use. ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... Dec. 19 House Republican Whip,Roy Blunt (Mo.) issued ... funding under the State Children,s Health Insurance,Program (SCHIP) through ... days of the first session of the 110th,Congress, the ... for months - a proposal to extend the current ...
... IDEXX Laboratories,Inc. (Nasdaq: IDXX ), announced today ... Conference. Jonathan W. Ayers, Chairman,President and CEO, is scheduled ... 7, 2008 at 8:00 a.m. (PT), at the Westin ... live audio webcast of,the presentation through a link on ...
... Stronger National,Measures, Urges America,s Health Insurance Plan Proposal ... The National Patient,Advocate Foundation (NPAF) -- a national, ... to health care through state and,federal public policy ... today in its Individual Market Guarantee Access,Proposal that ...
... introduce NutreStore(TM) in spring 2008, TORRANCE, ... a,Torrance, California based pharmaceutical company, announced today ... agreement with Cato BioVentures of,Research Triangle Park, ... brand L-Glutamine. Under this agreement, Emmaus will,commercialize ...
... happiness and sadness. Although lost opportunities and mistaken expectations ... experiences may impact personality development and overall happiness. A ... the University of Missouri, indicates that individuals who take ... more likely to mature and achieve a potentially more ...
... in tumor-suppressing gene could point to lymph node involvement, ... Supposedly "innocent" cells in the area surrounding cancerous tumors ... can predict whether or not the cancer spreads to ... of alterations in the tumor-suppressing p53 gene in the ...
Cached Medicine News:Health News:Leading National Patient Advocacy Group Commends Insurance Industry's Recognition, Focus on Growing National Problem of Uninsured and Underinsured Americans 2Health News:Leading National Patient Advocacy Group Commends Insurance Industry's Recognition, Focus on Growing National Problem of Uninsured and Underinsured Americans 3Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 2Health News:Emmaus Medical, Inc. Enters Into Sub-License Agreement for Treatment of Short Bowel Syndrome 3Health News:What's the rush? Taking time to acknowledge loss is not that bad 2Health News:Area Around Breast Tumor May Predict Cancer's Spread 2Health News:Area Around Breast Tumor May Predict Cancer's Spread 3
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
Medicine Products: